JP2018536023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536023A5 JP2018536023A5 JP2018541090A JP2018541090A JP2018536023A5 JP 2018536023 A5 JP2018536023 A5 JP 2018536023A5 JP 2018541090 A JP2018541090 A JP 2018541090A JP 2018541090 A JP2018541090 A JP 2018541090A JP 2018536023 A5 JP2018536023 A5 JP 2018536023A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- glycoprotein
- vaccine according
- vaccine
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccines Drugs 0.000 claims 27
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 11
- 229920000023 polynucleotide Polymers 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 230000000890 antigenic Effects 0.000 claims 7
- 102000003886 Glycoproteins Human genes 0.000 claims 6
- 108090000288 Glycoproteins Proteins 0.000 claims 6
- -1 cationic lipid Chemical class 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 5
- 238000007385 chemical modification Methods 0.000 claims 5
- 108010005593 glycoprotein D-herpes simplex virus type 2 Proteins 0.000 claims 5
- 108010016004 herpes simplex virus type 2 glycoprotein C Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 101710025088 66 Proteins 0.000 claims 3
- 101700008945 ICP4 Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- AMMRPAYSYYGRKP-BGZDPUMWSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-ethylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AMMRPAYSYYGRKP-BGZDPUMWSA-N 0.000 claims 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1H-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N Pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 229940035893 Uracil Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
Claims (21)
- 脂質ナノ粒子内に製剤化された単純ヘルペスウイルス(HSV)抗原性ポリペプチドをコードするオープンリーディングフレームを有するリボ核酸(RNA)ポリヌクレオチドを含む、HSVワクチンであって、
前記脂質ナノ粒子が、イオン性カチオン性脂質と、非カチオン性脂質と、ステロールと、PEG修飾脂質とを含み、
前記RNAポリヌクレオチドがメッセンジャーリボ核酸(mRNA)である、HSVワクチン。 - 前記抗原性ポリペプチドが、HSV−2糖タンパク質B、HSV−2糖タンパク質C、HSV−2糖タンパク質D、HSV−2糖タンパク質E、HSV−2糖タンパク質IS、及びHSV−2 ICP4タンパク質から選択される、請求項1に記載のHSVワクチン。
- (i)HSV−2糖タンパク質B、HSV−2糖タンパク質C、HSV−2糖タンパク質D、HSV−2糖タンパク質E、HSV−2糖タンパク質IS、及びHSV−2 ICP4タンパク質から選択される2つのHSV抗原性ポリペプチドをコードするオープンリーディングフレームを有するRNAポリヌクレオチドであって、場合によりHSV−2糖タンパク質CとHSV−2糖タンパク質DとをコードするRNAポリヌクレオチド、あるいは
(ii)HSV−2糖タンパク質B、HSV−2糖タンパク質C、HSV−2糖タンパク質D、HSV−2糖タンパク質E、HSV−2糖タンパク質IS、及びHSV−2 ICP4タンパク質から選択される少なくとも1つのHSV抗原性ポリペプチドをコードするオープンリーディングフレームをそれぞれ有する2つのRNAポリヌクレオチドであって、場合によりHSV−2糖タンパク質CとHSV−2糖タンパク質DとをコードするRNAポリヌクレオチド
を含む、請求項1または2に記載のHSVワクチン。 - 前記抗原性ポリペプチドが、配列番号24〜53または66〜77のうちのいずれか1つのアミノ酸配列に対して少なくとも90%、少なくとも95%、または95%〜99%の同一性を有するアミノ酸配列を含む、請求項1〜3のいずれか一項に記載のHSVワクチン。
- 前記抗原性ポリペプチドが、配列番号24〜53または66〜77のうちのいずれか1つのアミノ酸配列を含む、請求項4に記載のHSVワクチン。
- 前記RNAポリペプチドが、配列番号1〜23もしくは54〜64のうちのいずれか1つのアミノ酸配列に対して少なくとも90%、少なくとも95%、または95%〜99%の同一性を有する核酸配列によってコードされる、あるいは、前記RNAポリペプチドが、配列番号90〜124のうちのいずれか1つの核酸配列に対して少なくとも90%、少なくとも95%、または95%〜99%の同一性を有する核酸配列を含む、請求項1〜3のいずれか一項に記載のHSVワクチン。
- 前記RNAポリペプチドが、配列番号1〜23もしくは54〜64のうちのいずれか1つの核酸配列によってコードされる、あるいは前記RNAポリペプチドが、配列番号90〜124のうちのいずれか1つの核酸配列を含む、請求項5に記載のHSVワクチン。
- 前記ポリヌクレオチドがコードされるオープンリーディングフレームがコドン最適化された、請求項1〜7のいずれか一項に記載のHSVワクチン。
- 前記RNAポリヌクレオチドが、少なくとも1つの化学修飾を含む、請求項1〜8のいずれか一項に記載のHSVワクチン。
- (i)前記化学修飾が、プソイドウリジン、N1−メチルプソイドウリジン、N1−エチルプソイドウリジン、2−チオウリジン、4’−チオウリジン、5−メチルシトシン、2−チオ−1−メチル−1−デアザ−プソイドウリジン、2−チオ−1−メチル−プソイドウリジン、2−チオ−5−アザ−ウリジン、2−チオ−ジヒドロプソイドウリジン、2−チオ−ジヒドロウリジン、2−チオ−プソイドウリジン、4−メトキシ−2−チオ−プソイドウリジン、4−メトキシ−プソイドウリジン、4−チオ−1−メチル−プソイドウリジン、4−チオ−プソイドウリジン、5−アザ−ウリジン、ジヒドロプソイドウリジン、5−メトキシウリジン及び2’−O−メチルウリジンから選択される、請求項9に記載のHSVワクチン。
- 前記オープンリーディングフレーム中のウラシルの80%から100%が化学修飾を有する、請求項9または10に記載のHSVワクチン。
- 前記化学修飾がウラシルの5位にある、請求項9〜11のいずれか一項に記載のHSVワクチン。
- 前記化学修飾がN1−メチルプソイドウリジンである、請求項9〜12のいずれか一項に記載のHSVワクチン。
- 前記脂質ナノ粒子が、イオン化カチオン性脂質20〜60モル%、非カチオン性脂質5〜25モル%、ステロール25〜55モル%及びPEG修飾脂質0.5〜15モル%を含む、請求項1〜13のいずれか一項に記載のHSVワクチン。
- 前記非カチオン性脂質が中性脂質であり、前記ステロールがコレステロールである、請求項1〜14のいずれか一項に記載のHSVワクチン。
- 前記RNAポリヌクレオチドは、
(i)場合により7mG(5’)ppp(5’)N1mpNpであるか、これを含む、5’末端キャップと、
(ii)少なくとも1つのHSV抗原性ポリペプチドをコードするオープンリーディングフレームと、
(iii)3’ポリAテールと
を有する、請求項1〜15のいずれか一項に記載のHSVワクチン。 - 対象において抗原特異的免疫応答を誘導する方法にて使用するための請求項1〜16のいずれか一項に記載のHSVワクチンであって、前記方法は、抗原特異的免疫応答をもたらすのに有効な量で前記ワクチンを投与することを含む、前記HSVワクチン。
- 前記抗原特異的免疫応答がT細胞の応答またはB細胞の応答を含む、請求項17に記載のHSVワクチン。
- 前記方法が前記ワクチンの単回用量、または前記ワクチンの初回用量及び2回目(ブースター)用量の投与を含む、請求項17または18に記載のHSVワクチン。
- 前記ワクチンが、皮内注射または筋肉注射によって投与される、請求項17〜19のいずれか一項に記載のHSVワクチン。
- 前記有効量が50μg〜1000μgの総用量である、請求項17〜20のいずれか一項に記載のHSVワクチン。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021204272A JP2022037134A (ja) | 2015-10-22 | 2021-12-16 | 単純ヘルペスウイルスワクチン |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245031P | 2015-10-22 | 2015-10-22 | |
US201562245159P | 2015-10-22 | 2015-10-22 | |
US62/245,159 | 2015-10-22 | ||
US62/245,031 | 2015-10-22 | ||
US201562247576P | 2015-10-28 | 2015-10-28 | |
US62/247,576 | 2015-10-28 | ||
US201562248252P | 2015-10-29 | 2015-10-29 | |
US62/248,252 | 2015-10-29 | ||
PCT/US2016/058322 WO2017070623A1 (en) | 2015-10-22 | 2016-10-21 | Herpes simplex virus vaccine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021204272A Division JP2022037134A (ja) | 2015-10-22 | 2021-12-16 | 単純ヘルペスウイルスワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018536023A JP2018536023A (ja) | 2018-12-06 |
JP2018536023A5 true JP2018536023A5 (ja) | 2020-08-13 |
Family
ID=58558127
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541090A Pending JP2018536023A (ja) | 2015-10-22 | 2016-10-21 | 単純ヘルペスウイルスワクチン |
JP2021204272A Pending JP2022037134A (ja) | 2015-10-22 | 2021-12-16 | 単純ヘルペスウイルスワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021204272A Pending JP2022037134A (ja) | 2015-10-22 | 2021-12-16 | 単純ヘルペスウイルスワクチン |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180303929A1 (ja) |
EP (1) | EP3365009A4 (ja) |
JP (2) | JP2018536023A (ja) |
KR (1) | KR20180096593A (ja) |
CN (1) | CN108472355A (ja) |
AU (2) | AU2016342049B2 (ja) |
BR (1) | BR112018008090A2 (ja) |
CA (1) | CA3002822A1 (ja) |
CL (1) | CL2018001056A1 (ja) |
CO (1) | CO2018005258A2 (ja) |
EA (1) | EA201890999A1 (ja) |
IL (1) | IL258833A (ja) |
MA (1) | MA46024A (ja) |
MX (1) | MX2018004918A (ja) |
PE (1) | PE20181531A1 (ja) |
PH (1) | PH12018500855A1 (ja) |
SG (1) | SG11201803365RA (ja) |
TN (1) | TN2018000155A1 (ja) |
WO (1) | WO2017070623A1 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
LT3134131T (lt) | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
TW201729838A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
SI3386484T1 (sl) | 2015-12-10 | 2022-06-30 | Modernatx, Inc. | Sestave in metode za dovajanje terapevtskih sredstev |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
CA3024500A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
EP3555289A1 (en) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna affinity purification |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
WO2018170256A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
EP3615060A4 (en) * | 2017-04-26 | 2021-06-09 | Merck Sharp & Dohme Corp. | HSV ANTIGENIC PEPTIDES AND HSV PROTEIN VACCINES |
WO2018200737A1 (en) * | 2017-04-26 | 2018-11-01 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
WO2019035066A1 (en) * | 2017-08-17 | 2019-02-21 | The Trustees Of The University Of Pennsylvania | MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF |
MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
EP3999093A4 (en) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | ANTIGEN GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
BR112022000710A2 (pt) * | 2019-07-21 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Vacina viral terapêutica |
WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
AU2021261471A1 (en) | 2020-04-22 | 2022-11-17 | BioNTech SE | Coronavirus vaccine |
EP4175967A2 (en) | 2020-07-02 | 2023-05-10 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024512394A (ja) * | 2021-03-11 | 2024-03-19 | レッドバイオテック・アーゲー | Hsvを処置するためのワクチン組成物及び方法 |
CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023147090A1 (en) * | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1993001301A1 (en) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Mutant antiviral regulatory proteins |
GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
JP2001508649A (ja) * | 1996-11-04 | 2001-07-03 | スミスクライン・ビーチャム・コーポレイション | 2型単純ヘルペスウイルス由来の新規コーディング配列 |
JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
MXPA02012198A (es) * | 2000-06-09 | 2004-08-19 | Teni Boulikas | Encapsulacion de polinucleotidos y drogas en liposomas objetivos. |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
WO2003011443A2 (en) | 2001-07-27 | 2003-02-13 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
CA2462593A1 (en) | 2001-10-03 | 2003-04-10 | Kam W. Leong | Compositions for oral gene therapy and methods of using same |
AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
EP1691780A2 (en) * | 2003-11-21 | 2006-08-23 | Alza Corporation | Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
MXPA06011871A (es) | 2004-04-15 | 2007-10-08 | Chiasma Inc | Composiciones capaces de facilitar la penetracion a traves de una barrera biologica. |
WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
ATE440117T1 (de) | 2005-04-01 | 2009-09-15 | Intezyne Technologies Inc | Polymermicellen für die arzneistoffzufuhr |
US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
EP2279758B1 (en) | 2005-06-16 | 2015-02-25 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
US9149543B2 (en) * | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
JP5312050B2 (ja) | 2006-02-21 | 2013-10-09 | ネクター セラピューティクス | 分割型の分解性重合体とそれから生成される複合体 |
EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
CA2652426A1 (en) * | 2006-05-19 | 2007-11-29 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions |
CA2658484A1 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
WO2008030557A2 (en) | 2006-09-08 | 2008-03-13 | Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
PL2644192T3 (pl) | 2007-09-28 | 2017-09-29 | Pfizer Inc. | Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek |
EA021422B1 (ru) | 2008-06-16 | 2015-06-30 | Бинд Терапьютикс, Инк. | Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения |
ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
HUE035770T2 (en) | 2008-06-16 | 2018-05-28 | Pfizer | Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
ES2776126T3 (es) | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
US8287910B2 (en) | 2009-04-30 | 2012-10-16 | Intezyne Technologies, Inc. | Polymeric micelles for polynucleotide encapsulation |
CN102712935B (zh) | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
EP2512459A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME | |
EA201290497A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP5988435B2 (ja) | 2010-01-24 | 2016-09-07 | ノバルティス アーゲー | 放射線照射された生分解性微粒子 |
US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
EP2575895A2 (en) | 2010-05-24 | 2013-04-10 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
WO2011163483A2 (en) | 2010-06-25 | 2011-12-29 | Massachusetts Institute Of Technology | Polymers for biomaterials and therapeutics |
BR112013000392B8 (pt) * | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
ES2716243T3 (es) * | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT |
CA2816977C (en) | 2010-11-05 | 2019-10-29 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
KR20140007404A (ko) * | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법 |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
US9901554B2 (en) | 2011-03-31 | 2018-02-27 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
WO2012131106A1 (en) | 2011-03-31 | 2012-10-04 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2729126B1 (en) * | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
JP6018197B2 (ja) | 2011-07-21 | 2016-11-02 | クローダ インターナショナル パブリック リミティド カンパニー | 分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法 |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
EP2750712A2 (en) | 2011-08-31 | 2014-07-09 | Mallinckrodt LLC | Nanoparticle peg modification with h-phosphonates |
JP2014531456A (ja) | 2011-09-22 | 2014-11-27 | バインド セラピューティックス インコーポレイテッド | 治療用ナノ粒子と癌を治療する方法 |
WO2013072929A2 (en) | 2011-09-23 | 2013-05-23 | Indian Institute Of Technology | Nanop article based cosmetic composition |
JP6305925B2 (ja) * | 2011-10-11 | 2018-04-18 | ノバルティス アーゲー | 組換え自己複製ポリシストロニックrna分子 |
CN103987847B (zh) | 2011-10-18 | 2017-06-16 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
EA032088B1 (ru) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
LT2791160T (lt) * | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
EP2804632B1 (en) | 2012-01-19 | 2019-09-18 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
JP6182159B2 (ja) | 2012-02-03 | 2017-08-16 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | フェノール性単量体から誘導された高分子生体材料およびその医療用途 |
CN104105750A (zh) | 2012-02-10 | 2014-10-15 | 纳幕尔杜邦公司 | 高-x两嵌段共聚物的制备、纯化和使用 |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
JP6561378B2 (ja) * | 2012-06-08 | 2019-08-21 | トランスレイト バイオ, インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
US20150366997A1 (en) * | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
EP2931319B1 (en) * | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
EA201591293A1 (ru) * | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки антител, кодируемых мрнк |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
HUE039189T2 (hu) * | 2013-03-15 | 2018-12-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
LT3134131T (lt) * | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
WO2018226638A1 (en) * | 2017-06-05 | 2018-12-13 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing hsv icp0 protein |
-
2016
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en active Active
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/en active Application Filing
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
- 2016-10-21 CA CA3002822A patent/CA3002822A1/en active Pending
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/en active Pending
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko unknown
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
-
2018
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en active Pending
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018536023A5 (ja) | ||
JP2018531996A5 (ja) | ||
JP2018536022A5 (ja) | ||
JP2019501208A5 (ja) | ||
JP2019535665A5 (ja) | ||
US11965000B2 (en) | Respiratory syncytial virus (RSV) vaccine | |
US11964010B2 (en) | Prefusion coronavirus spike proteins and their use | |
Kon et al. | Principles for designing an optimal mRNA lipid nanoparticle vaccine | |
Park et al. | mRNA vaccines for COVID-19: what, why and how | |
JP2018537521A5 (ja) | ||
JP2023116608A5 (ja) | ||
RU2018118337A (ru) | Вакцина против вируса гриппа широкого спектра действия | |
JP2021504445A5 (ja) | ||
Begum et al. | Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development | |
JP2013507907A5 (ja) | ||
Miura et al. | A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant | |
RU2016145597A (ru) | Вакцины на основе нуклеиновых кислот | |
JP2001500112A (ja) | ネコのポリヌクレオチドワクチン処方 | |
JP2013524780A5 (ja) | ||
Schöne et al. | Immunodominance of adenovirus-derived CD8+ T cell epitopes interferes with the induction of transgene-specific immunity in adenovirus-based immunization | |
Elia et al. | Lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against a lethal SARS-CoV-2 infection | |
CN113226364A (zh) | 组合物和方法 | |
Gargett et al. | Increase in DNA vaccine efficacy by virosome delivery and co‐expression of a cytolytic protein | |
JP2010535504A5 (ja) | ||
Raza et al. | Prediction and analysis of multi epitope based vaccine against Newcastle disease virus based on haemagglutinin neuraminidase protein |